Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Madrigal Pharmaceuticals's total debt was $340.79M at Jun 30, 2026. For fiscal 2025 it was $339.88M, up 189.1% from the year before. The highest annual figure on record is $339.88M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $339.88M | +189.1% |
| FY2024 | Dec 31, 2024 | $117.57M | +1.8% |
| FY2023 | Dec 31, 2023 | $115.48M | +134.3% |
| FY2022 | Dec 31, 2022 | $49.29M | – |
| FY2021 | Dec 31, 2021 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $340.79M | +187.9% |
| Q1 FY2026 | Mar 31, 2026 | $340.33M | +188.4% |
| Q4 FY2025 | Dec 31, 2025 | $339.88M | +189.1% |
| Q3 FY2025 | Sep 30, 2025 | $339.75M | +190.2% |
| Q2 FY2025 | Jun 30, 2025 | $118.38M | +1.5% |
| Q1 FY2025 | Mar 31, 2025 | $118.01M | +1.6% |
| Q4 FY2024 | Dec 31, 2024 | $117.57M | +1.8% |
| Q3 FY2024 | Sep 30, 2024 | $117.09M | +2.1% |
| Q2 FY2024 | Jun 30, 2024 | $116.61M | +17.5% |
| Q1 FY2024 | Mar 31, 2024 | $116.14M | +38.3% |
| Q4 FY2023 | Dec 31, 2023 | $115.48M | +134.3% |
| Q3 FY2023 | Sep 30, 2023 | $114.73M | +134.2% |
| Q2 FY2023 | Jun 30, 2023 | $99.25M | +103.9% |
| Q1 FY2023 | Mar 31, 2023 | $83.97M | – |
| Q4 FY2022 | Dec 31, 2022 | $49.29M | – |
| Q3 FY2022 | Sep 30, 2022 | $48.98M | – |
| Q2 FY2022 | Jun 30, 2022 | $48.67M | – |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
See a number that looks wrong?